Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.32 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 59.47 |
| Open | 59.35 |
| 1-Year Change | -49.14% |
| Day's Range | 59.35 - 61.74 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 61.64 | 2.92 | 4.97% | 58.72 | 61.81 | 58.72 |
| Apr 23, 2025 | 59.47 | -2.36 | -3.82% | 61.83 | 62.49 | 58.83 |
| Apr 22, 2025 | 59.22 | 3.77 | 6.80% | 55.45 | 59.28 | 55.45 |
| Apr 21, 2025 | 55.14 | 2.39 | 4.53% | 52.75 | 55.88 | 52.75 |
| Apr 17, 2025 | 53.72 | 0.37 | 0.69% | 53.35 | 55.25 | 53.30 |
| Apr 16, 2025 | 53.86 | -0.32 | -0.59% | 54.18 | 54.83 | 52.91 |
| Apr 15, 2025 | 54.33 | 0.59 | 1.10% | 53.74 | 56.04 | 53.19 |
| Apr 14, 2025 | 54.53 | 1.63 | 3.08% | 52.90 | 54.57 | 51.05 |
| Apr 11, 2025 | 50.25 | -0.15 | -0.30% | 50.40 | 51.62 | 48.83 |
| Apr 10, 2025 | 50.06 | -3.13 | -5.88% | 53.19 | 53.52 | 49.76 |
| Apr 9, 2025 | 54.95 | 6.50 | 13.42% | 48.45 | 57.38 | 47.86 |
| Apr 8, 2025 | 49.25 | -4.67 | -8.66% | 53.92 | 54.92 | 48.77 |
| Apr 7, 2025 | 52.18 | 0.78 | 1.52% | 51.40 | 54.82 | 50.15 |
| Apr 4, 2025 | 54.33 | -3.85 | -6.62% | 58.18 | 58.54 | 54.09 |
| Apr 3, 2025 | 58.29 | 0.48 | 0.83% | 57.81 | 59.83 | 57.42 |
| Apr 2, 2025 | 61.96 | 0.94 | 1.54% | 61.02 | 64.11 | 60.41 |
| Apr 1, 2025 | 61.56 | -2.65 | -4.13% | 64.21 | 65.45 | 61.26 |
| Mar 31, 2025 | 63.18 | -2.47 | -3.76% | 65.65 | 66.95 | 62.25 |
| Mar 28, 2025 | 69.92 | -1.00 | -1.41% | 70.92 | 71.86 | 69.54 |
| Mar 27, 2025 | 71.33 | -0.72 | -1.00% | 72.05 | 73.43 | 71.20 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com